Insider filings

Beam Therapeutics Inc. (BEAM)

Biotechnology, listed on NASDAQ.

20 insider transactionslast filed Oct 16, 2026

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

EarningsQ3 FY2026 · reported Nov 3, 2026

Q3 FY2026: EPS miss, GAAP. Revenue missed by 96.5%. Next report Feb 23, 2027.

EPS Q3 FY2026

Reported-$1.28
Consensus-$1.15

Revenue Q3 FY2026

Reported$307K
Consensus$8.75M

Beat 2Miss 4

EPS against the consensus, quarter by quarter. Outlined: a GAAP figure against an adjusted consensus.

Consensus -$1.28 a share on $5.65M of revenue, the analysts’ forecast.

Every quarter

Money managers13F filings for Sep 30, 2026

3

of the fund managers in GetSignal’s fund directory list Beam Therapeutics among their largest positions. Cathie Wood held the most, $288.6M.

Every manager

Insider tradesForm 4 · 9 open-market filings shown

Nine open-market sales, 7 of them under 10b5‑1 plans.

Jun 25, 2026Oct 16, 2026

SalesSales under a plan

7 of 9 under a plan

A median 1 business day from trade to filing. Form 4 is due within two.

Every filing
Companyfrom the company's filings and listing, as of Nov 18, 2026

About Beam Therapeutics Inc.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Chief executive
John Evans
Employees
540
Listed since
Feb 6, 2020
Market value
$2.1B
Price to earnings (12 mo)
-
Net income per share, as reported (12 mo)
-$1.02
Dividend yield
-

www.beamtx.com

GetSignal News1 article · newest first

GetSignal News

HeadlineSourceDate
Risto-cel meets primary endpoint of at least 12 months free of severe VOCsBeam Therapeutics also said the study met all secondary endpoints and expects to submit a U.S. biologics license application as early as year-end 2026.Company releaseNov 10, 2026

Written by GetSignal with AI from SEC filings and the company's own press releases; each article links to its source. Not investment advice.

All company news

Earnings6 reported quarters · next on Feb 23, 2027

Earnings

QuarterEPSEPS expectedRevenueRevenue expectedResult
Q3 FY2026reported Nov 3, 2026-$1.28-$1.15$307K$8.8MEPS miss, GAAPRevenue miss
Q2 FY2026reported Aug 4, 2026-$1.18-$1.11$490K$16.4MEPS miss, GAAPRevenue miss
Q1 FY2026reported May 7, 2026-$0.91-$0.87$31.7M$11.0MEPS miss, GAAPRevenue beat
Q4 FY2025reported Feb 24, 2026-$0.10-$1.13$114.1M$11.7MEPS beatRevenue beat
Q3 FY2025reported Nov 4, 2025-$1.10-$0.98$9.7M$13.2MEPS miss, GAAPRevenue miss
Q2 FY2025reported Aug 5, 2025-$1.00-$1.04$8.5M$11.5MEPS beat, GAAPRevenue miss

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

No earnings call briefs on BEAM yet. All earnings call briefs.

Proxy statementas filed for fiscal 2025 · proxy filed Apr 17, 2026

Executive pay

John Evans’s pay as CEO came to $5.8M for fiscal 2025.
ExecutiveSalaryStock awardsOtherTotal
John EvansCEO$755K$1.5M$3.5M$5.8M
Giuseppe Ciaramella, Ph.D.President$668K$684K$1.8M$3.2M
Amy Simon, M.D. CMO$550K$884K$1.4M$2.8M
Christine Bellon, Ph.D.CLO$511K$391K$1.1M$2.0M
Sravan K. EmanyCFO$575K$0$722K$1.3M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing

13F filings13F positions as of Sep 30, 2026

Institutional holders

191 institutions reported Beam Therapeutics shares in 13F filings for Sep 30, 2026.
HolderValueSharesShares vs prior qtr% of shares out
FMR LLC$316.1M12,926,476+2.5%12.39%
ARK Investment Management LLCCathie Wood$288.6M11,805,372+15.3%11.32%
Farallon Capital Management, L.L.C.$251.3M10,276,396+0.4%9.85%
BlackRock, Inc.$223.0M9,119,097+1.4%8.74%
State Street Corp$144.8M5,920,492+1.6%5.67%
Vanguard Portfolio Management LLC$119.8M4,901,651-0.4%4.70%
Vanguard Capital Management LLC$112.7M4,608,292+0.2%4.42%
Arch Venture Management, LLC$111.0M4,540,1320.0%4.35%
Kynam Capital Management, LP$96.2M3,933,894+38.5%3.77%
Sumitomo Mitsui Trust Group, Inc.$81.9M3,349,244-3.1%3.21%
Amova Asset Management Americas, Inc.$81.8M3,349,244-3.1%3.21%
Geode Capital Management, LLC$61.5M2,514,059-3.2%2.41%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Sep 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

13F filings3 managers

Fund managers holding BEAM

ManagerValueSharesShare of book
Cathie WoodARK Invest$288.6M11,805,3721.7%
Farallon Capital$251.3M10,276,3961.1%
Stanley DruckenmillerDuquesne Family Office$17.1M699,7000.4%

3 of the fund managers in GetSignal’s fund directory list BEAM shares among the largest positions in their latest 13F, filed for Q3 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.

Form 49 filings shown · newest filing first

Open-market insider trades

InsiderActionSharesPriceValueTrade dateDelay
(business days)
John M. EvansCEOSold · scheduled25,000$23.98$600KOct 16, 2026filed Oct 16, 20260d
John M. EvansCEOSold · scheduled25,000$23.57$589KOct 15, 2026filed Oct 16, 20261d
Bethany J. CavanaghSVP, Finance and TreasurerSold · scheduled187$24.41$5KOct 1, 2026filed Oct 2, 20261d
Amy SimonChief Medical OfficerSold · scheduled16,667$25.74$429KJul 27, 2026filed Jul 29, 20262d
Amy SimonChief Medical OfficerSold · scheduled373$34.73$13KJun 30, 2026filed Jul 2, 20262d
John M. EvansCEOSold · scheduled · 2 lines25,000$34.31$858KJun 30, 2026filed Jul 1, 20261d
John M. EvansCEOSold · scheduled · 2 lines25,000$35.49$887KJun 29, 2026filed Jul 1, 20262d
FMR LLC10% ownerSold251,488$35.26$8.9MJun 26, 2026filed Jun 29, 20261d
FMR LLC10% ownerSold33,372$35.12$1.2MJun 25, 2026filed Jun 29, 20262d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (7)
InsiderEventSharesDate
John M. EvansCEOOption exercise25,000Oct 15, 2026
John M. EvansCEOOption exercise25,000Oct 16, 2026
Giuseppe CiaramellaPresidentGift123,407Sep 24, 2026
John M. EvansCEOOption exercise25,000Jun 29, 2026
John M. EvansCEOOption exercise25,000Jun 30, 2026
Giuseppe CiaramellaPresidentOption exercise35,505Jun 17, 2026
Christi ShawDirectorStock award19,676Jun 3, 2026

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.

Data as of Nov 21, 2026.

Methodology · Guide to Form 4 · Guide to the STOCK Act

Questions

What the filings on BEAM show and how current they are.

Are insiders buying or selling BEAM?

Across the 9 most recent open-market filings shown here, 0 were purchases and 9 were sales. 7 were scheduled in advance under a Rule 10b5-1 plan.

How quickly are BEAM trades disclosed?

Insider filings on this page reached the public a median of 1 business day after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows.

Related companies

also in Healthcare

Stocks A to Z